Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus DECABID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus DECABID.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY vs DECABID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
None Documented
None Documented
14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Primarily fecal (80%) and renal (11%) as unchanged drug.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination